A Randomized, Placebo-controlled, Double-blind, In-patient Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 Following a Single Dose in Subjects With Type 1 Diabetes Mellitus

Trial Profile

A Randomized, Placebo-controlled, Double-blind, In-patient Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 Following a Single Dose in Subjects With Type 1 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs REMD 477 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors REMD Biotherapeutics
  • Most Recent Events

    • 13 Jun 2017 Primary endpoint (Changes from baseline in 24-hour insulin requirements on Day 1 relative to the two 24 hour periods post-treatment on Day 4, between the REMD-477 and placebo treated subjects, needed to maintain targeted glycemic control.) has been met as per the results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 13 Jun 2017 Results (n=17) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Results published in the the American Diabetes Association Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top